Geneva, June 20 -- International Clinical Trials Registry received information related to the study (NCT07020832) titled 'A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation' on June 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Apellis Pharmaceuticals, Inc.
Condition:
Delayed Graft Function
End Stage Renal Disease
Deceased Donor Kidney Transplant
Intervention:
Drug: Pegcetacoplan
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enro...